---
document_datetime: 2026-01-20 16:15:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/elfabrio.html
document_name: elfabrio.html
version: success
processing_time: 0.1086931
conversion_datetime: 2026-01-20 20:30:02.967468
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.69.0
  docling-core: 2.60.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Search

- [Medicines](/en/medicines)
    - [Find medicine](/en/medicines)
    - [Therapeutic areas: latest updates](/en/medicines/therapeutic-areas-latest-updates)
    - [Download medicine data](/en/medicines/download-medicine-data)
    - [What we publish on medicines and when](/en/medicines/what-we-publish-medicines-when)
    - [Medicines under evaluation](/en/medicines/medicines-human-use-under-evaluation)
    - [National registers](/en/medicines/national-registers-authorised-medicines)
- [Human regulatory](/en/human-regulatory-overview)
    - [Overview](/en/human-regulatory-overview)
    - [Research and development](/en/human-regulatory-overview/research-development)
    - [Marketing authorisation](/en/human-regulatory-overview/marketing-authorisation)
    - [Post-authorisation](/en/human-regulatory-overview/post-authorisation)
    - [Medical devices](/en/human-regulatory-overview/medical-devices)
    - [Herbal products](/en/human-regulatory-overview/herbal-medicinal-products)
- [Veterinary regulatory](/en/veterinary-regulatory-overview)
    - [Overview](/en/veterinary-regulatory-overview)
    - [Research and development](/en/veterinary-regulatory-overview/research-development-veterinary-medicines)
    - [Marketing authorisation](/en/veterinary-regulatory-overview/marketing-authorisation-veterinary-medicines)
    - [Post-authorisation](/en/veterinary-regulatory-overview/post-authorisation-veterinary-medicines)
- [Committees](/en/committees)
    - [Overview](/en/committees)
    - [How the committees work](/en/committees/how-committees-work)
    - [CHMP](/en/committees/committee-medicinal-products-human-use-chmp)
    - [CVMP](/en/committees/committee-veterinary-medicinal-products-cvmp)
    - [PRAC](/en/committees/pharmacovigilance-risk-assessment-committee-prac)
    - [COMP](/en/committees/committee-orphan-medicinal-products-comp)
    - [HMPC](/en/committees/committee-herbal-medicinal-products-hmpc)
    - [CAT](/en/committees/committee-advanced-therapies-cat)
    - [PDCO](/en/committees/paediatric-committee-pdco)
    - [Working parties and other groups](/en/committees/working-parties-other-groups)
- [News &amp; events](/en/news-events)
    - [Overview](/en/news-events)
    - [News](/en/news)
    - [Events](/en/events/upcoming-events)
    - [What's new](/en/news-events/whats-new)
    - [Committee highlights](/en/news-events/committee-highlights)
    - [Publications](/en/news-and-events/publications)
    - [Press and social media](/en/news-events/press-social-media)
    - [Podcast: Inside EMA](/en/news-events/podcast-inside-ema)
    - [Open consultations](/en/news-events/open-consultations)
    - [RSS feeds](/en/news-events/rss-feeds)
- [Partners &amp; networks](/en/partners-networks)
    - [Overview](/en/partners-networks)
    - [Animal health practitioners](/en/partners-networks/animal-health-practitioners)
    - [One Health approach](/en/partners-networks/one-health-approach)
    - [Academia](/en/partners-networks/academia)
    - [EU partners](/en/partners-networks/eu-partners)
    - [International activities](/en/partners-networks/international-activities)
    - [Patients and consumers](/en/partners-networks/patients-consumers)
    - [Healthcare professionals](/en/partners-networks/healthcare-professionals)
    - [Pharmaceutical industry](/en/partners-networks/pharmaceutical-industry)
    - [Networks](/en/partners-networks/networks)
    - [Health technology assessment bodies](/en/partners-networks/health-technology-assessment-bodies)
- [About us](/en/about-us)
    - [Overview](/en/about-us)
    - [What we do](/en/about-us/what-we-do)
    - [Who we are](/en/about-us/who-we-are)
    - [How we work](/en/about-us/how-we-work)
    - [Fees](/en/about-us/fees-payable-european-medicines-agency)
    - [Support to SMEs](/en/about-us/support-smes)
    - [Annual reports and work programmes](/en/about-us/annual-reports-work-programmes)
    - [History of EMA](/en/about-us/history-ema)
    - [Careers](/en/about-us/careers)
    - [Procurement](/en/about-us/procurement-grants)
    - [Glossaries](/en/about-us/glossaries)
    - [About this website](/en/about-us/about-website)
    - [Data protection and privacy](/en/about-us/data-protection-privacy-ema)
    - [Contacts](/en/about-us/contacts-european-medicines-agency)

1. [Home](/en/homepage)
2. [Medicines](https://www.ema.europa.eu/en/medicines)
3. Elfabrio

# Elfabrio

[RSS](/en/individual-human-medicine.xml/67665)

##### Authorised

This medicine is authorised for use in the European Union

pegunigalsidase alfa Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Elfabrio](#news-on)
- [More information on Elfabrio](#more-information-on-elfabrio-958)
- [More information on Elfabrio](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Elfabrio is a medicine used in adults to treat Fabry disease, a rare inherited disorder. Patients with Fabry disease do not have enough of an enzyme, called alpha-galactosidase A, that normally breaks down a fatty substance called globotriaosylceramide (Gb3). If the enzyme is not present, Gb3 cannot be broken down and it builds up in the organs, such as the kidney and heart, causing kidney failure and heart problems.

Elfabrio contains the active substance pegunigalsidase alfa.

Expand section

Collapse section

## How is Elfabrio used?

Elfabrio can only be obtained with a prescription and treatment should be supervised by a doctor with experience in treating Fabry disease.

Elfabrio is available as an infusion (drip) into a vein, which is given once every two weeks. It is intended for long-term use. All patients are monitored for any reactions during the infusion and for at least one to two hours afterwards. To reduce the risk of infusion-related reactions, patients may be given other medicines before or during treatment with Elfabrio or the infusion time may be slowed down. The infusions are given in hospital but may be given at home if the patient is tolerating the infusions well.

For more information about using Elfabrio, see the package leaflet or contact your doctor or pharmacist.

## How does Elfabrio work?

Elfabrio is an enzyme replacement therapy. This type of therapy provides patients with the enzyme they are lacking. Elfabrio is designed to replace the human enzyme alpha-galactosidase A, which is lacking in patients with Fabry disease. The active substance in Elfabrio, pegunigalsidase alfa, is a copy of the human enzyme, produced by a method known as 'recombinant DNA technology': it is made by cells that have received a gene (DNA), which makes them able to produce the enzyme. The replacement enzyme helps to break down Gb-3 and stops it building up in the patient's cells.

## What benefits of Elfabrio have been shown in studies?

The benefits of Elfabrio were evaluated in one main study, involving 78 patients with Fabry disease. The study compared Elfabrio with Fabrazyme, another enzyme replacement therapy used to treat patients with Fabry disease. The main measure of effectiveness was based on glomerular filtration rate (GFR; a measure of how well the kidneys are working), which decreases as a patient's kidney function gets worse. The average GFR reduced by 2.5 mL/min/1.73m2 per year after both 12 and 24 months of treatment with Elfabrio compared with 1.7 mL/min/1.73m2 and 2.2 mL/min/1.73m2 in those who received Fabrazyme. Supportive data showed a significant decrease in the levels of Gb3 in the kidneys and blood of patients treated with Elfabrio.

## What are the risks associated with Elfabrio?

For the full list of side effects and restrictions with Elfabrio, see the package leaflet.

The most common side effects with Elfabrio (which may affect up to 1 in 10 people) include hypersensitivity (allergic reactions), asthenia (weakness) and infusion-associated reactions.

Allergic reactions, including excessive and prolonged contraction of the airway muscles causing breathing difficulty (bronchospasm), can occur in people receiving Elfabrio.

## Why is Elfabrio authorised in the EU?

The Agency considered that the efficacy of Elfabrio was supported by nature of the active substance, specifically that it is a pegylated form of the natural occurring enzyme, and also by the well-established mechanism of action of enzyme replacement therapy in the treatment of Fabry disease. Results from the main study showed a significant decrease in the levels of Gb3 in both the kidneys and blood of patients treated with Elfabrio. Due to limitations with the study design, including the small number of patients involved, results of the main study did not conclusively show that Elfabrio was at least as effective as Fabrazyme.

Furthermore, the side effects of Elfabrio, which are mainly related to the infusion, are considered manageable. The European Medicines Agency therefore decided that Elfabrio's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Elfabrio?

The company that markets Elfabrio will provide educational materials to patients or their carers and to healthcare professionals, with information on how to give the product correctly within the home setting.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Elfabrio have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Elfabrio are continuously monitored. Suspected side effects reported with Elfabrio are carefully evaluated and any necessary action taken to protect patients.

## Other information about Elfabrio

Elfabrio received a marketing authorisation valid throughout the EU on 4 May 2023.

Elfabrio : EPAR - Medicine Overview

Reference Number: EMA/210775/2023

English (EN) (95.92 KB - PDF)

**First published:** 08/05/2023

[View](/en/documents/overview/elfabrio-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-37)

български (BG) (119.58 KB - PDF)

**First published:**

08/05/2023

[View](/bg/documents/overview/elfabrio-epar-medicine-overview_bg.pdf)

español (ES) (96.62 KB - PDF)

**First published:**

08/05/2023

[View](/es/documents/overview/elfabrio-epar-medicine-overview_es.pdf)

čeština (CS) (114.88 KB - PDF)

**First published:**

08/05/2023

[View](/cs/documents/overview/elfabrio-epar-medicine-overview_cs.pdf)

dansk (DA) (96.01 KB - PDF)

**First published:**

08/05/2023

[View](/da/documents/overview/elfabrio-epar-medicine-overview_da.pdf)

Deutsch (DE) (96.91 KB - PDF)

**First published:**

08/05/2023

[View](/de/documents/overview/elfabrio-epar-medicine-overview_de.pdf)

eesti keel (ET) (94.62 KB - PDF)

**First published:**

08/05/2023

[View](/et/documents/overview/elfabrio-epar-medicine-overview_et.pdf)

ελληνικά (EL) (128.17 KB - PDF)

**First published:**

08/05/2023

[View](/el/documents/overview/elfabrio-epar-medicine-overview_el.pdf)

français (FR) (97.02 KB - PDF)

**First published:**

08/05/2023

[View](/fr/documents/overview/elfabrio-epar-medicine-overview_fr.pdf)

hrvatski (HR) (109.89 KB - PDF)

**First published:**

08/05/2023

[View](/hr/documents/overview/elfabrio-epar-medicine-overview_hr.pdf)

italiano (IT) (103.87 KB - PDF)

**First published:**

08/05/2023

[View](/it/documents/overview/elfabrio-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (124.81 KB - PDF)

**First published:**

08/05/2023

[View](/lv/documents/overview/elfabrio-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (121.93 KB - PDF)

**First published:**

08/05/2023

[View](/lt/documents/overview/elfabrio-epar-medicine-overview_lt.pdf)

magyar (HU) (109.96 KB - PDF)

**First published:**

08/05/2023

[View](/hu/documents/overview/elfabrio-epar-medicine-overview_hu.pdf)

Malti (MT) (115.79 KB - PDF)

**First published:**

08/05/2023

[View](/mt/documents/overview/elfabrio-epar-medicine-overview_mt.pdf)

Nederlands (NL) (96.63 KB - PDF)

**First published:**

08/05/2023

[View](/nl/documents/overview/elfabrio-epar-medicine-overview_nl.pdf)

polski (PL) (115.95 KB - PDF)

**First published:**

08/05/2023

[View](/pl/documents/overview/elfabrio-epar-medicine-overview_pl.pdf)

português (PT) (96.47 KB - PDF)

**First published:**

08/05/2023

[View](/pt/documents/overview/elfabrio-epar-medicine-overview_pt.pdf)

română (RO) (121.65 KB - PDF)

**First published:**

08/05/2023

[View](/ro/documents/overview/elfabrio-epar-medicine-overview_ro.pdf)

slovenčina (SK) (114.06 KB - PDF)

**First published:**

08/05/2023

[View](/sk/documents/overview/elfabrio-epar-medicine-overview_sk.pdf)

slovenščina (SL) (109.62 KB - PDF)

**First published:**

08/05/2023

[View](/sl/documents/overview/elfabrio-epar-medicine-overview_sl.pdf)

Suomi (FI) (95.66 KB - PDF)

**First published:**

08/05/2023

[View](/fi/documents/overview/elfabrio-epar-medicine-overview_fi.pdf)

svenska (SV) (95.81 KB - PDF)

**First published:**

08/05/2023

[View](/sv/documents/overview/elfabrio-epar-medicine-overview_sv.pdf)

Elfabrio : EPAR - Risk management plan summary

English (EN) (262.69 KB - PDF)

**First published:** 08/05/2023

[View](/en/documents/rmp-summary/elfabrio-epar-risk-management-plan-summary_en.pdf)

## Product information

Elfabrio : EPAR - Product Information

English (EN) (427.56 KB - PDF)

**First published:** 08/05/2023

**Last updated:** 20/01/2026

[View](/en/documents/product-information/elfabrio-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-428)

български (BG) (469.14 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/01/2026

[View](/bg/documents/product-information/elfabrio-epar-product-information_bg.pdf)

español (ES) (420.82 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/01/2026

[View](/es/documents/product-information/elfabrio-epar-product-information_es.pdf)

čeština (CS) (453 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/01/2026

[View](/cs/documents/product-information/elfabrio-epar-product-information_cs.pdf)

dansk (DA) (426.1 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/01/2026

[View](/da/documents/product-information/elfabrio-epar-product-information_da.pdf)

Deutsch (DE) (429.21 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/01/2026

[View](/de/documents/product-information/elfabrio-epar-product-information_de.pdf)

eesti keel (ET) (417.15 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/01/2026

[View](/et/documents/product-information/elfabrio-epar-product-information_et.pdf)

ελληνικά (EL) (482.61 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/01/2026

[View](/el/documents/product-information/elfabrio-epar-product-information_el.pdf)

français (FR) (432.95 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/01/2026

[View](/fr/documents/product-information/elfabrio-epar-product-information_fr.pdf)

hrvatski (HR) (446.45 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/01/2026

[View](/hr/documents/product-information/elfabrio-epar-product-information_hr.pdf)

íslenska (IS) (420.02 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/01/2026

[View](/is/documents/product-information/elfabrio-epar-product-information_is.pdf)

italiano (IT) (424.49 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/01/2026

[View](/it/documents/product-information/elfabrio-epar-product-information_it.pdf)

latviešu valoda (LV) (463.19 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/01/2026

[View](/lv/documents/product-information/elfabrio-epar-product-information_lv.pdf)

lietuvių kalba (LT) (466.81 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/01/2026

[View](/lt/documents/product-information/elfabrio-epar-product-information_lt.pdf)

magyar (HU) (490.59 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/01/2026

[View](/hu/documents/product-information/elfabrio-epar-product-information_hu.pdf)

Malti (MT) (501.82 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/01/2026

[View](/mt/documents/product-information/elfabrio-epar-product-information_mt.pdf)

Nederlands (NL) (428.37 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/01/2026

[View](/nl/documents/product-information/elfabrio-epar-product-information_nl.pdf)

norsk (NO) (415.2 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/01/2026

[View](/no/documents/product-information/elfabrio-epar-product-information_no.pdf)

polski (PL) (493.01 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/01/2026

[View](/pl/documents/product-information/elfabrio-epar-product-information_pl.pdf)

português (PT) (426.42 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/01/2026

[View](/pt/documents/product-information/elfabrio-epar-product-information_pt.pdf)

română (RO) (454.65 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/01/2026

[View](/ro/documents/product-information/elfabrio-epar-product-information_ro.pdf)

slovenčina (SK) (490.16 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/01/2026

[View](/sk/documents/product-information/elfabrio-epar-product-information_sk.pdf)

slovenščina (SL) (466.2 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/01/2026

[View](/sl/documents/product-information/elfabrio-epar-product-information_sl.pdf)

Suomi (FI) (423.69 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/01/2026

[View](/fi/documents/product-information/elfabrio-epar-product-information_fi.pdf)

svenska (SV) (419.03 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/01/2026

[View](/sv/documents/product-information/elfabrio-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000319765 20/01/2026

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Elfabrio : EPAR - All authorised presentations

English (EN) (50.15 KB - PDF)

**First published:** 08/05/2023

**Last updated:** 20/11/2024

[View](/en/documents/all-authorised-presentations/elfabrio-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-493)

български (BG) (37.78 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/11/2024

[View](/bg/documents/all-authorised-presentations/elfabrio-epar-all-authorised-presentations_bg.pdf)

español (ES) (13.82 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/11/2024

[View](/es/documents/all-authorised-presentations/elfabrio-epar-all-authorised-presentations_es.pdf)

čeština (CS) (43.97 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/11/2024

[View](/cs/documents/all-authorised-presentations/elfabrio-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (23.9 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/11/2024

[View](/da/documents/all-authorised-presentations/elfabrio-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (14.54 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/11/2024

[View](/de/documents/all-authorised-presentations/elfabrio-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (14.38 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/11/2024

[View](/et/documents/all-authorised-presentations/elfabrio-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (37.78 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/11/2024

[View](/el/documents/all-authorised-presentations/elfabrio-epar-all-authorised-presentations_el.pdf)

français (FR) (21.88 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/11/2024

[View](/fr/documents/all-authorised-presentations/elfabrio-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (33.87 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/11/2024

[View](/hr/documents/all-authorised-presentations/elfabrio-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (21.85 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/11/2024

[View](/is/documents/all-authorised-presentations/elfabrio-epar-all-authorised-presentations_is.pdf)

italiano (IT) (14.12 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/11/2024

[View](/it/documents/all-authorised-presentations/elfabrio-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (35.58 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/11/2024

[View](/lv/documents/all-authorised-presentations/elfabrio-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (40.3 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/11/2024

[View](/lt/documents/all-authorised-presentations/elfabrio-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (22.06 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/11/2024

[View](/hu/documents/all-authorised-presentations/elfabrio-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (43.98 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/11/2024

[View](/mt/documents/all-authorised-presentations/elfabrio-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (22.34 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/11/2024

[View](/nl/documents/all-authorised-presentations/elfabrio-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (22.57 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/11/2024

[View](/no/documents/all-authorised-presentations/elfabrio-epar-all-authorised-presentations_no.pdf)

polski (PL) (33.73 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/11/2024

[View](/pl/documents/all-authorised-presentations/elfabrio-epar-all-authorised-presentations_pl.pdf)

português (PT) (14.28 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/11/2024

[View](/pt/documents/all-authorised-presentations/elfabrio-epar-all-authorised-presentations_pt.pdf)

română (RO) (43.53 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/11/2024

[View](/ro/documents/all-authorised-presentations/elfabrio-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (30.88 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/11/2024

[View](/sk/documents/all-authorised-presentations/elfabrio-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (21.98 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/11/2024

[View](/sl/documents/all-authorised-presentations/elfabrio-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (14.09 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/11/2024

[View](/fi/documents/all-authorised-presentations/elfabrio-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (14.28 KB - PDF)

**First published:**

08/05/2023

**Last updated:**

20/11/2024

[View](/sv/documents/all-authorised-presentations/elfabrio-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Elfabrio Active substance pegunigalsidase alfa International non-proprietary name (INN) or common name pegunigalsidase alfa Therapeutic area (MeSH) Fabry Disease Anatomical therapeutic chemical (ATC) code A16AB20

### Pharmacotherapeutic group

Other alimentary tract and metabolism products

### Therapeutic indication

Elfabrio is indicated for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease (deficiency of alpha-galactosidase).

## Authorisation details

EMA product number EMEA/H/C/005618 Marketing authorisation holder

Chiesi Farmaceutici S.p.A

Via Palermo 26/A

Opinion adopted 23/02/2023 Marketing authorisation issued 04/05/2023 Revision 3

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Elfabrio : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (143.81 KB - PDF)

**First published:** 20/01/2026

[View](/en/documents/procedural-steps-after/elfabrio-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Elfabrio : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (145.98 KB - PDF)

**First published:** 20/11/2024

**Last updated:** 20/01/2026

[View](/en/documents/procedural-steps-after/elfabrio-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Elfabrio : Orphan designation withdrawal assessment report (initial-authorisation)

Adopted

Reference Number: EMA/OD/0000109504

English (EN) (515.99 KB - PDF)

**First published:** 08/05/2023

[View](/en/documents/orphan-maintenance-report/elfabrio-orphan-designation-withdrawal-assessment-report-initial-authorisation_en.pdf)

Elfabrio : EPAR - Public Assessment Report

Adopted

Reference Number: EMA/58745/2023

English (EN) (3.85 MB - PDF)

**First published:** 08/05/2023

[View](/en/documents/assessment-report/elfabrio-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Elfabrio

Adopted

Reference Number: EMA/CHMP/60808/2023

English (EN) (96.68 KB - PDF)

**First published:** 24/02/2023

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-elfabrio_en.pdf)

#### News on Elfabrio

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20 - 23 February 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-february-2023) 24/02/2023

#### More information on Elfabrio

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu-3-17-1953) on 12 December 2017. Pegunigalsidase alfa was withdrawn from the Union Register of orphan medicinal products by the European Commission in March 2023 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.

#### More information on Elfabrio

- [EMEA-001828-PIP01-15-M03 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001828-pip01-15-m03)

**This page was last updated on** 20/01/2026

## Share this page

[Back to top](#main-content)